Consulting Chief Medical Officer at Amylyx
Dr. Yeramian joined Amylyx as Chief Medical Officer in 2019 bringing to the company more than 30 years of pharmaceutical industry experience. He was previously the consulting medical director for Amylyx, where he has supported the pre-IND and IND filings of AMX0035 for the treatment of amyotrophic lateral sclerosis and Alzheimer’s disease, and has overseen the design and execution of both clinical trials. Throughout his career Dr. Yeramian has supervised the clinical development of new drugs, biopharmaceuticals, cellular therapy agents and vaccines. He has held prominent roles in the approval of several drug (metronidazole – Flagyl MR®), biological (interferon alpha – Multiferon®, nafarelin – Synarel®) and device (Inerpan®) applications by the FDA and EMA and granting of more than 20 successful INDs and IMPDs. Previously he served as Chief Medical Officer at Viragen, Inc. where he was responsible for the development of global clinical and regulatory strategies and for the implementation of clinical programs worldwide. Earlier in his career, Dr. Yeramian served as Director of clinical research at GD Searle where he supervised the clinical programs for antibiotics, antivirals, sepsis/thrombosis and cancer vaccines. He also previously served as Medical Director of the Vaccine and Gene Therapy Institute in Florida. Dr. Yeramian holds a Medical Degree from the University of Paris together with a Master of Clinical Science in experimental oncology and a Graduate Degree in molecular virology. He received his Master of Business Administration from Rutgers University. He completed his medical residency in oncology at the Saint-Louis Hospital in Paris.
Consulting Chief Medical Officer